SCGP is advancing its growth strategy in the healthcare supplies market by expanding into the production of syringes and needles in Thailand. In collaboration with Once Medical Company Limited (ONCE), the partnership leverages ONCE's expertise to co-develop products. Production is expected to commence in January 2026, with products distributed to healthcare facilities in Thailand and both domestic and international distributors.
Wichan Jitpukdee, Chief Executive Officer, SCG Packaging Public Company Limited or SCGP, said that the company is implementing a strategy to enhance its capabilities in the growing healthcare supplies market, which continues to show strong growth potential. This involves entering the syringes and needles market. Recently, the company's board of directors approved an investment project to expand syringes production capacity by 180 million units per year and needles production by 100 million units per year at VEM (Thailand) Company Limited (VEM-TH) in SCGP, Rayong Province, with a total investment of Baht 142.3 million. Production is expected to begin in January 2026.
For this production capacity expansion, SCGP has partnered with ONCE, which has over 20 years of experience in needle development and distribution. This collaboration will facilitate the production of syringes and needles at VEM-TH, which specializes in injection molding, medical device component manufacturing, and high-precision plastic parts. Production will adhere to certified Cleanroom ISO8, under a rigorous production control system. The goal is to manufacture quality products under the ONCE brand and distribute them to healthcare facilities nationwide, as well as to both domestic and international distributors. This partnership will build upon ONCE's existing customer base, which already has confidence in the brand, while also expanding its reach to new customers. Furthermore, the collaboration will extend to the joint development of other medical devices and equipment.
The global healthcare supplies market presents consistent growth, with an expected annual growth rate of 4.0% from 2024 to 2027. Currently, the majority of products sold in Thailand are imported. Establishing a production base in Thailand will enhance the ability to meet customer demands more effectively and support the growing healthcare market in Thailand. This production increase will enable SCGP to leverage its expertise in rigid plastic packaging and flexible packaging, extending its reach into the healthcare supplies business. This involves advanced product design and high-precision manufacturing capabilities. Furthermore, it fosters growth through synergies across the entire value chain, including the manufacturing of healthcare and medical products in collaboration with VEM-TH, and provides opportunities to increase revenue through sales channels of Deltalab, S.L. in Spain.